These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34326139)

  • 21. Infigratinib: First Approval.
    Kang C
    Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition.
    Lee JY; Lee SY; Oh SJ; Lee KH; Jung YS; Kim SK
    Chem Biol Interact; 2012 Jun; 198(1-3):49-56. PubMed ID: 22652334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.
    Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW
    Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
    Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
    Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
    Foo WY; Tay HY; Chan EC; Lau AJ
    Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.
    Wen B; Chen Y; Fitch WL
    Drug Metab Dispos; 2009 Jul; 37(7):1557-62. PubMed ID: 19364830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of lapatinib with cytochrome P450 3A5.
    Chan EC; New LS; Chua TB; Yap CW; Ho HK; Nelson SD
    Drug Metab Dispos; 2012 Jul; 40(7):1414-22. PubMed ID: 22511346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation.
    Tang LWT; Chan ECY
    Biochem Pharmacol; 2022 Dec; 206():115336. PubMed ID: 36332675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Xenobiotica; 2016 Dec; 46(12):1056-1065. PubMed ID: 26928326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
    Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
    Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
    Loos NHC; Beijnen JH; Schinkel AH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
    Alvarez-Diez TM; Zheng J
    Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.
    Foti RS; Rock DA; Pearson JT; Wahlstrom JL; Wienkers LC
    Drug Metab Dispos; 2011 Jul; 39(7):1188-95. PubMed ID: 21447734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
    Karkhanis A; Lam HY; Venkatesan G; Koh SK; Chai CL; Zhou L; Hong Y; Kojodjojo P; Chan EC
    Biochem Pharmacol; 2016 May; 107():67-80. PubMed ID: 26972388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
    Filppula AM; Laitila J; Neuvonen PJ; Backman JT
    Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor.
    Masubuchi Y; Kawaguchi Y
    Biopharm Drug Dispos; 2013 Nov; 34(8):423-30. PubMed ID: 23929629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.